We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.20 | 3.03% | 40.76 | 40.59 | 40.80 | 40.80 | 40.12 | 40.15 | 2,775,124 | 22:20:00 |
From Jul 2022 to Jul 2024
By Cecilia Butini
Shares in biopharmaceutical company MorphoSys AG slid on Monday after licensing partner Roche Holding AG's drug trial for Alzheimer's disease failed.
At 0958 GMT, MorphoSys shares traded 32% down at EUR14.35.
MorphoSys has been in a collaboration agreement with Roche since 2000, whereby Roche is responsible for the clinical development of Alzheimer's drug gantenerumab and MorphoSys is entitled to royalties and milestone payments.
Roche said Monday that studies of gantenerumab didn't meet primary endpoints of slowing clinical decline in patients with the disease.
The market will now pivot its focus back to MorphoSys's lymphoma drug Monjuvi and the Phase 3 trial of cancer drug pelabresib, as royalties from Roche are no longer contributing to company valuation, Citi analyst Vineet Agrawal said in a note. Sentiment on MorphoSys's stock is likely to remain poor, Mr. Agrawal said, as the bank dowgrades it to sell.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
November 14, 2022 05:15 ET (10:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
